Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Clinical Utility Study

April 8, 2021
RNS Number : 7571U Renalytix AI PLC 08 April 2021       Renalytix AI plc   (" RenalytixAI " or the " Company ")     Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions   Value of KidneyIntelX Testing Demonstrated by Data from 401

Clinical findings published in Diabetologia

April 6, 2021
RNS Number : 4091U Renalytix AI PLC 06 April 2021       Renalytix AI plc   (" RenalytixAI " or the " Company ")     Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure  

Update on Finalization of MCIT Rule

March 15, 2021
RNS Number : 1874S Renalytix AI PLC 15 March 2021   Renalytix AI plc (" RenalytixAI " or the " Company ")   Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics   NEW YORK , March 15, 2021 - Renalytix AI plc   (LSE : RENX) (NASDAQ:

Issue of shares, PDMR Dealing and TVR

March 4, 2021
RNS Number : 2460R Renalytix AI PLC 04 March 2021     Renalytix AI plc ("RenalytixAI", the "Company" or the "Group")   Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights   New York , 4 March 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),, an

Financial Results for Second Quarter of FY 2021

March 2, 2021
RNS Number : 8363Q Renalytix AI PLC 02 March 2021   RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021   NEW YORK , March 2, 2021   - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics

Half-year Report

March 2, 2021
RNS Number : 8349Q Renalytix AI PLC 02 March 2021     Renalytix AI plc ("RenalytixAI", the "Company" or the "Group")   Half-year Report   Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on

University of Utah Kidney Health Partnership

February 24, 2021
RNS Number : 1616Q Renalytix AI PLC 24 February 2021   This announcement contains inside information   Renalytix AI plc (" RenalytixAI " or the " Company ")   The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health   Innovative partnership to enable health system-wide

Notice of Results

February 23, 2021
RNS Number : 9649P Renalytix AI PLC 23 February 2021     Renalytix AI plc (" RenalytixAI " or the " Company ")   RenalytixAI to announce Financial Results for six and three months ended December 31, 2020   NEW YORK , February 23, 2021   - Renalytix AI plc   (LSE : RENX) (NASDAQ: RNLX), the

ASN & Renalytix to Co-Host Capital Markets Day

February 4, 2021
RNS Number : 9849N Renalytix AI PLC 04 February 2021     Renalytix AI plc (" RenalytixAI " or the " Company ")   American Society of Nephrology and Renalytix to Co-Host Virtual Capital Markets Day for Kidney Health     Event Featuring Leading Clinicians, Biotech Innovators and Federal Health

Price Monitoring Extension

January 13, 2021
RNS Number : 6057L Renalytix AI PLC 13 January 2021   Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
Displaying 1 - 10 of 118